Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Down 88.3% in May

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a large decline in short interest in May. As of May 31st, there was short interest totalling 92,400 shares, a decline of 88.3% from the May 15th total of 787,500 shares. Based on an average daily volume of 122,400 shares, the short-interest ratio is presently 0.8 days. Approximately 18.0% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of Applied DNA Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd.

Applied DNA Sciences Trading Down 0.4%

NASDAQ:APDN opened at $4.65 on Thursday. The firm has a market capitalization of $344,100.00, a price-to-earnings ratio of -0.81 and a beta of 0.06. The firm’s fifty day simple moving average is $11.18 and its 200 day simple moving average is $78.33. Applied DNA Sciences has a twelve month low of $4.37 and a twelve month high of $2,655.00.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings data on Thursday, May 15th. The technology company reported ($230.25) EPS for the quarter, missing analysts’ consensus estimates of ($45.00) by ($185.25). The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.19 million. Applied DNA Sciences had a negative return on equity of 101.57% and a negative net margin of 228.12%. On average, analysts predict that Applied DNA Sciences will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Applied DNA Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of APDN. Millennium Management LLC acquired a new position in Applied DNA Sciences during the 4th quarter worth approximately $28,000. Connective Capital Management LLC acquired a new position in shares of Applied DNA Sciences during the fourth quarter worth $36,000. Geode Capital Management LLC lifted its position in shares of Applied DNA Sciences by 291.1% during the fourth quarter. Geode Capital Management LLC now owns 417,485 shares of the technology company’s stock worth $85,000 after purchasing an additional 310,749 shares in the last quarter. Finally, Anson Funds Management LP acquired a new position in shares of Applied DNA Sciences during the first quarter worth $349,000. 22.22% of the stock is owned by institutional investors and hedge funds.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.